Brief: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1B Clinical Trial Of Mupadolimab In China
26/09/2022 21:14
Sept 26 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS ANNOUNCES PARTNER ANGEL
PHARMACEUTICALS
RECEIVED IND APPROVAL FOR PHASE 1/1B CLINICAL TRIAL OF
MUPADOLIMAB (ANTI-CD73) IN CHINA
Source text for Eikon: ID:nGNX7p8LNP
Further company coverage: CRVS.O
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental